Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.
- Conditions
- Colitis, Ulcerative
- Registration Number
- NCT06025227
- Lead Sponsor
- Pfizer
- Brief Summary
Provide pre-approval single patient Expanded Access (Compassionate Use) of Etrasimod for patients.
- Detailed Description
In Expanded Access, treating physicians are the Sponsors. Expanded Access requests from treating physicians may be submitted to www.pfizercares.com. Availability will depend on location and country.
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Etrasimod's S1P receptor modulation in ulcerative colitis treatment?
How does Etrasimod's efficacy in compassionate use compare to standard-of-care biologics like anti-TNF agents for UC?
Which biomarkers correlate with response to Etrasimod in S1P receptor-mediated pathways for ulcerative colitis?
What adverse events are associated with Etrasimod compassionate use, and how are they managed in clinical practice?
How does Etrasimod's S1P1/4/5 receptor profile differ from other modulators like Ozanimod in UC therapeutic approaches?